GlassScriptPhysician profile
Michael L Aikens
NPI 1427014844
$2,895.25
in general payments reported to CMS, 2019-2025
25 companies · $99.87 in 2025
The $99.87 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $1,101 · 2021: $115 · 2022: $560 · 2023: $46.95 · 2024: $233 · 2025: $99.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $412.14 | 2019-2020 | |
| Medtronic, INC. | $289.70 | 2021-2023 | Venaseal |
| Janssen Pharmaceuticals, INC | $263.43 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $257.49 | 2022-2025 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $251.98 | 2019-2020 | |
| Amarin Pharma, INC. | $250.49 | 2019-2020 | |
| Tactile Systems Technology INC | $192.25 | 2019-2023 | Flexitouch Plus, Entre Plus |
| United Therapeutics Corporation | $188.04 | 2019-2020 | |
| Pfizer INC. | $136.74 | 2020 | |
| Amgen INC. | $91.73 | 2019-2020 | |
| Lilly USA, LLC | $79.66 | 2024 | Mounjaro |
| Smith+Nephew, INC. | $69.99 | 2019 | |
| Kerecis Limited | $64.88 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Alnylam Pharmaceuticals INC. | $54.28 | 2022 | |
| Boston Scientific Corporation | $50.26 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocompatibles, INC. | $37.36 | 2019 | |
| Medtronic Vascular, INC. | $36.65 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.23 | 2019-2020 | |
| Cardiovascular Systems INC. | $31.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $31.15 | 2020 | |
| Medicomp INC | $17.79 | 2019 | |
| Abbott Laboratories | $16.29 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.70 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.33 | 2024 | Eliquis |
| Vivus LLC | $8.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Aikens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.